Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.

Clinical lung cancer - 1 Jul 2025

Waliany Sarah, Hung Yin P, Rous Fawzi Abu, Luo Faustine, Capelletti Marzia, Ressler Steven, Do Andrew, Peterson Jennifer, Meservey Caitlin, Digumarthy Subba R, Ou Sai-Hong Ignatius, Gadgeel Shirish M, Lin Jessica J, Meador Catherine B

Abstract excerpt

BACKGROUND: Effective treatments for patients with advanced lung carcinoids remain limited. The prevalence of potentially actionable genomic alterations (AGAs) among lung carcinoids is not well-understood. MATERIALS AND METHODS: Lung carcinoids submitted for next-generation sequencing (NGS) at a Clinical Laboratory Improvement Amendments (CLIA)-certified genomics laboratory from September 2013 to March 2024 were...

Read the complete abstract on PubMed

Topics

Humans
Lung Neoplasms
Carcinoid Tumor
Male
Middle Aged
Female

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Molecular Targeted Therapy

Retrospective Studies

Aged

Mutation

Adult

High-Throughput Nucleotide Sequencing

Genomics

Biomarkers, Tumor

Prognosis

Aged, 80 and over

Follow-Up Studies

Source

Open in PubMed Open full text

Identifiers

PMID: 40234130
DOI: 10.1016/j.cllc.2025.03.009
PMCID: PMC12176514

Genes

ALK
RET
AGA
BRAF
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.PMID 40234130Read ↗

Molecular Profiling Across 80,000 Patients With Lung Cancer.Semantic proximity Read ↗

Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors.Semantic proximity Read ↗

Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.Semantic proximity Read ↗

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.Semantic proximity Read ↗

Genomic Landscape of NSCLC in the Republic of IrelandSemantic proximity Read ↗

Identification of Actionable Gene Variants in Pulmonary Large-Cell Neuroendocrine Carcinoma: A Real-World Analysis of a Polish Cohort.Semantic proximity Read ↗

Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country.Semantic proximity Read ↗

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Semantic proximity Read ↗

Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.Semantic proximity Read ↗

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer.Semantic proximity Read ↗

Lung Cancer: Targeted Therapy in 2025Semantic proximity Read ↗

Next-Generation Sequencing Reveals Distinct Molecular Patterns in Lung Cancer: KRAS-Driven Adenocarcinoma and Limited Comutations in EGFR-Mutated TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.